Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer

Table 1 Summary of stereotactic body radiotherapy for liver metastasis

Ref.	Study	Patients (n) (primary sites)	Meta (n)	Institution	MFU (mo)	Dose (Gy)/fr	Time (d)	Prescription specification	LC (mo)	OS (mo)	Toxicity	P value
Herfarth et al[50]	P I	CRC (n = 18) others (n = 14)	60-	Heidelberg Univ	15	14-26/1	1	Isocenter, PTV surrounded by 80% isodose	0% (24)	32% (24)	N MT	P < 0.01
	P II					26/1	1		81% (24)	83% (24)
Wulf et al[51]	Retro	39	CRC (n = 23) others (n = 28)	Wuerzburg Univ	15	28-30/3-4	2-3 interval	PTV periphery: 65% isodose of maximum	58% (24)	81% (24 for all)	N MT	P = 0.08
						36-37.5/3 or 26/1			82% (24)
Katz et al[52]	Retro	CRC (n = 20) others (n = 49)	174	Rochester Univ	15	50/5f preferred	14	Maximum, PTV surrounded by the 80% isodose	57% (20)	37% (20)	N MT
Rusthoven et al[53]	P I/II	CRC (n = 20) others (n = 49)	63	Multi-institution	16	36-60/3	< 14	Isocenter, PTV surrounded by 80%-90% isodose	92% (24)	30% (24)	Grade 3: 2%
Lee et al[54]	P I	CRC (n = 40) others (n = 28)	-	Princess Margaret Hospital	11	27.7-60/6 (median: 41.8)	> 14	PTV periphery: 71% isodose of maximum	71% (12)	47% (18)	N MT
van der Pool et al[55]	Retro	CRC (n = 20)	31	Erasmus Univ	26	37.5-45/3f preferred	5-6	D95 of PTV	74% (24)	83% (24)	N MT
Rule et al[56]	P I	CRC (n = 12) others (n = 15)	36	Texas Southwestern Univ	20	3/30	< 14	PTV periphery, 70%-85% isodose of maximum	59% (24)	56% (24)	N MT
						50/5	≤ 17		89% (24)	67% (24)
						60/5	≤ 17		100% (24)	50% (24)
Vautravers- Dewas et al[57]	Retro	CRC (n = 30) others (n = 15)	62	Centre Oscar Lambret	14	40/3	4-17	PTV periphery, 80% isodose of the maximum	86% (12)	48% (24 for all)	N MT	P = 0.07
						45/3	(mean: 9)		100% (12)
		CRC (n = 30)							86% (12)			P = 0.07
		others (n = 15)							100% (12)
Scorsetti et al[58]	P II	CRC (n = 29) others (n = 32)	76	Humanitas Cancer Center	12	52.5-75/3	3	Mean dose to PTV	90.6% (24)	37% (24)	N MT

MFU: Median follow up duration; LC: Local control rate; OS: Overall survival rate; P X: Phase X; retro: Retrospective; CRC: Colorectal cancer; fr: Fractions; PTV: Planning target volume; Dx: The dose delivered to x%; N MT: No major toxicity.

Table 2 Summary of stereotactic body radiotherapy for pulmonary metastasis

Ref.	Study	Patients (n) (primary sites)	Meta (n)	Institution	MFU (mo)	Dose (Gy)/	Time (d)	Prescription specification	LC (mo)	OS (mo)	Toxicity	P value
Wulf et al[70]	Retro	CRC (n = 4) others (n = 37)	51	Wuerzburg Univ	10	30-37.5/3 or 26/1	2-3 interval	PTV periphery: 65% isodose of maximum	80% (24)	33% (24)	N MT
Okunieff et al[71]	Retro	CRC (n = 14) others (n = 35)	125	Rochester Univ.	19	Oct-50	1-5 times per week	Isocenter	91% (24)	38% (24)	Grade 3 pleural effusion: 2%
Norihisa et al[72]	Retro	CRC (n = 14) others (n = 35)	43	Kyoto Univ.	27	48-60/4	4-18 (med: 12)	Isocenter	90% (24)	84.3% (24)	Grade 3 RP: 3%
Kim et al[73]	Retro	CRC (n = 13)	18	Korea Cancer Center	28	39-51/3	3	PTV periphery: 75%-80% isodose of maximum	53% (24)	76% (24)	N MT
Rusthoven et al[74]	P I/II	CRC (n = 9) others (n = 29)	63	multi-institution	15	48-60/3	< 14	Isocenter, PTV surrounded by 80%-90% isodose	96% (24)	39% (24)	Grade 3 RP: 8%
Takeda et al[44]	Retro	CRC (n = 15) others (n = 19)	CRC (n = 21) others (n = 23)	Ofuna Chuo Hospital	29	May-50	5	PTV periphery: 75%-80% isodose of maximum	72% (24)	-	N MT	P < 0.05
					15				94% (24)	-
Oh et al[75]	Retro	57	67	Samsung Medical Center	21	50-60/4-5	-	PTV periphery: 75%-80% isodose of maximum	92% (24)	57% (24)	Grade 5 RP: 2%
			CRC, HCC (n = 16) others (n = 51)						81% (24)			P = 0.01
									100% (24)
Ricardi et al[76]	Retro	61	77	Giovanni Battista Univ	20	26/1 or	3	PTV periphery: 80% isodose of maximum isocenter	89% (24)	66.5% (24)	Grade 3 RP: 2%
						36-45/3
Inoue et al[77]	Retro	22	31	Hokkaido Univ.	25	Apr-48	4-7		100% (24)	80% (24)	N MT
Widder et al[78]	Retro	CRC (n = 31) others (n = 11)	≥ 65	Groningen Univ	43	3/8/1960	-	PTV periphery: adapted risk of toxicity	94% (24)	86% (24)	-
Inoue et al[79]	Retro	CRC (n = 37) others (n = 50)	≥ 150	Miyakojima IGRT Clinic	15	48/4, 52-60/4 or 50/5	4-5	-	80% (24)	47% (24)	Grade 3 RP: 6% Grade4 RP: 1%

MFU: Median follow up duration; LC: Local control rate; OS: Overall survival rate; P X: Phase X; retro: Retrospective; CRC: Colorectal cancer; fr: Fractions; PTV: Planning target volume; Dx: The dose delivered to x%; N MT: No major toxicity; RP: Radiation pneumonitis.